Dr. Punnonen joins Hinge Bio with over 20 years of experience as a biopharmaceutical executive and drug developer in the fields of oncology and immuno-oncology BURLINGAME, Calif., May 30, 2023 /PRNewswire/ — Hinge Bio, Inc., a privately-held biotechnology company, today announced that…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.